HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK eyes FDA if no EMA deal

This article was originally published in OTC Bulletin & The Rose Sheet

Executive Summary

If the UK fails to secure full regulatory alignment with the European Union (EU) on medicines as part of negotiations over its ‘Brexit’ withdrawal from the EU, then the country may seek to align with the USFood and Drug Administration (FDA),according to a UK House of Commons health and social care committee report on the impact of Brexit on medicines.

Advertisement

Related Content

European Trade Groups To Cosmetics Firms: Be Prepared For ‘No Deal’ Brexit

Topics

Advertisement
UsernamePublicRestriction

Register

RS122112

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel